11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Suboptimal statin adherence and discontinuation in primary and secondary prevention populations.

      Journal of General Internal Medicine
      Cohort Studies, Coronary Disease, drug therapy, prevention & control, Cost-Benefit Analysis, Databases as Topic, Delivery of Health Care, Female, Financing, Personal, Hospitals, University, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, economics, therapeutic use, Male, Managed Care Programs, Middle Aged, Odds Ratio, Primary Prevention, Retrospective Studies, Risk, Survival Analysis, Treatment Refusal, statistics & numerical data, United States

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To compare statin nonadherence and discontinuation rates of primary and secondary prevention populations and to identify factors that may affect those suboptimal medication-taking behaviors. Retrospective cohort utilizing pharmacy claims and administrative databases. A midwestern U.S. university-affiliated hospital and managed care organization (MCO). Non-Medicaid MCO enrollees, 18 years old and older, who filled 2 or more statin prescriptions from January 1998 to November 2001; 2258 secondary and 2544 primary prevention patients were identified. Nonadherence was assessed by the percent of days without medication (gap) over days of active statin use, a measurement known as cumulative multiple refill-interval gap (CMG). Discontinuation was identified by cessation of statin refills prior to the end of available pharmacy claims data. On average, the primary and secondary groups went without medication 20.4% and 21.5% of the time, respectively (P=.149). Primary prevention patients were more likely to discontinue statin therapy relative to the secondary prevention cohort (relative risk [RR], 1.24; 95% confidence interval [CI], 1.08 to 1.43). Several factors influenced nonadherence and discontinuation. Fifty percent of patients whose average monthly statin copayment was < US dollars 10 discontinued by the end of follow-up (3.9 years), whereas 50% of those who paid >US dollars 10 but US dollars 20 discontinued by 2.2 and 1.0 years, respectively (RR, 1.39 and 4.30 relative to

          Related collections

          Author and article information

          Comments

          Comment on this article